Source:http://linkedlifedata.com/resource/pubmed/id/14748807
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2004-1-29
|
pubmed:abstractText |
Voriconazole is a new antifungal agent that can be given orally and intravenously. It has proven efficacy for treating candidosis and invasive aspergillosis as well as other mould infections, such as those caused by Fusarium and Scedosporium spp. The drug is generally well tolerated.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1198-743X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
10 Suppl 1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
107-17
|
pubmed:dateRevised |
2006-11-7
|
pubmed:meshHeading | |
pubmed:year |
2004
|
pubmed:articleTitle |
Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity.
|
pubmed:affiliation |
Department of Haematology, University Medical Center St Radboud, Nijmegen, The Netherlands. p.donnelly@usa.net
|
pubmed:publicationType |
Journal Article,
Review
|